Language: BG BG
← Back to results
Approved for marketing NCT00094029

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Conditions: Gastrointestinal Neoplasm

Sponsor: Pfizer

trial.available_in: БГ
Overview
The purpose of this study is to permit access to SU011248 for treatment use by patients with GIST given the following conditions: a) patients undergo screening, but are not eligible for participation in ongoing clinical studies such as A6181004; AND b) patients have GIST which standard treatments have not been able to control with acceptable toxicity AND c) patients have the potential to derive clinical benefit from treatment with SU011248.
Description
Given that an Expanded Access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per NIH, Basic Results for such studies are not required to be reported. Protocol A6181036 has been identified as an Expanded Access trial, and has been registered to ClinicalTrials.gov, however Basic Results will not be posted.
Who can participate
Inclusion Criteria: * Histologically proven Gastrointestinal Stomal Tumor (GIST) that is not amenable to standard therapy * Undergone screening and found to be ineligible for participation in ongoing SU011248 clinical studies * Patient judged to have potential to derive clinical benefit from SU011248 treatment by the treating physician * Failed prior treatment with imatinib mesylate, defined as either progression of disease or significant toxicity during treatment with imatinib mesylate that precluded further treatment * Male or Female, 18 years or older * Resolution of all acute toxicities of prior therapies * Adequate organ function Exclusion Criteria: * Symptomatic congestive heart failure, myocardial infarction, or coronary artery bypass graft in the last 6 months, or ongoing severe or unstable angina or any unstable arrhythmia requiring medication * Symptomatic central nervous system metastases * Serious acute or chronic illness * Current treatment on another clinical trial * Pregnant or breastfeeding.
Locations 31
Argentina (1)
Pfizer Investigational Site
Burnos Aires
Australia (1)
Pfizer Investigational Site
Camperdown , New South Wales
Belgium (1)
Pfizer Investigational Site
Brussels
Canada (1)
Pfizer Investigational Site
Calgary , Alberta
Chile (1)
Pfizer Investigational Site
Santiago , RM
Colombia (1)
Pfizer Investigational Site
Bogota , Cundinamarca
Czech Republic (1)
Pfizer Investigational Site
Brno
Denmark (1)
Pfizer Investigational Site
Aarhus C
Finland (1)
Pfizer Investigational Site
Helsinki
France (1)
Pfizer Investigational Site
Bordeaux
Greece (1)
Pfizer Investigational Site
Thessaloniki
Hong Kong (1)
Pfizer Investigational Site
Happy Valley , Hong Kong
Hungary (1)
Pfizer Investigational Site
Budapest
India (1)
Pfizer Investigational Site
Mumbai , Maharashtra
Israel (1)
Pfizer Investigational Site
Tel Aviv
Italy (1)
Pfizer Investigational Site
Candiolo (TO) , Italy
Mexico (1)
Pfizer Investigational Site
Guadalajara , Jalisco
Netherlands (1)
Pfizer Investigational Site
Groningen , Provincie Groningen
Norway (1)
Pfizer Investigational Site
Oslo
Poland (1)
Pfizer Investigational Site
Warsaw
Singapore (1)
Pfizer Investigational Site
Singapore
Slovakia (1)
Pfizer Investigational Site
Bratislava , Bratislava Region
South Korea (1)
Pfizer Investigational Site
Seoul
Spain (1)
Pfizer Investigational Site
Barcelona , Barcelona
Sweden (1)
Pfizer Investigational Site
Gothenburg
Taiwan (1)
Pfizer Investigational Site
Kaohsiung Hsien
Thailand (1)
Pfizer Investigational Site
Ratchatawi , Bangkok
Turkey (1)
Pfizer Investigational Site
Ankara
United Kingdom (1)
Pfizer Investigational Site
Leeds , England
United States (1)
Pfizer Investigational Site
Duarte , California
Venezuela (1)
Pfizer Investigational Site
Caracas , Distrito Federal
Technical details
Status
Approved for marketing
Study type
EXPANDED_ACCESS
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
01.09.2004
Completion date
01.10.2011
Registry ID
NCT00094029
Source
anzctr
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.